The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Trump Signs Order to Cut Routine Childhood Vaccines 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Nvidia CEO Says AGI Has Arrived With OpenAI GPT-6 Astra 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Milei Threatens Falkland Oil Firms With Sanctions 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Add as a preferred source on Google
Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and Drug Administration’s (FDA) new national priority voucher, positioning it for potentially accelerated approval. The pharmaceutical giant plans to submit its application this quarter, with the FDA set to determine the review timeline. Under the new program, qualifying drugs can receive review periods as short as one to two months, compared to the usual ten to twelve.
The criteria for the voucher program include innovation, addressing unmet medical needs, and supporting U.S. manufacturing—three areas in which Lilly claims strong alignment. The GLP-1 pill demonstrated significant effectiveness in late-stage trials, helping patients lose 12.4% of body weight, and Lilly has invested heavily in domestic production facilities to meet future demand.
The FDA recently announced the first nine recipients of this voucher, including Merck KGaA, Sanofi, and Regeneron, signaling heightened competition in the accelerated drug review space.
Alongside regulatory progress, Lilly reported a major earnings beat, driven by surging international demand for its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound. Third-quarter earnings reached $7.02 per share, well above analyst expectations of $5.69. Sales of Mounjaro totaled $6.5 billion, while Zepbound brought in $3.6 billion, both surpassing projections.
Lilly raised its full-year profit outlook to between $23.00 and $23.70 per share, up from previous guidance. The company now expects annual revenue between $63 billion and $63.5 billion. Analysts credit strong overseas demand and consistent consumer interest in weight-loss therapies for Lilly’s sustained growth, solidifying its leadership position against rival Novo Nordisk. As the global market for obesity drugs accelerates toward an estimated $150 billion by decade’s end, Eli Lilly continues to dominate the sector with robust innovation and expanding market share.
